HAMLET BIOPHARMA AB CLASS B
NNGM:HAMLET.B5.93
SEK
-0.04
(-0.67%)
HAMLET BIOPHARMA AB CLASS B
NGM:HAMLET.B
(Nordic Growth Market)
Recent
price
5.93
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Hamlet BioPharma AB is a clinical-stage biotechnology and pharmaceutical development company headquartered in Lund, Sweden, specializing in the research and commercialization of targeted therapeutics for oncology, infectious diseases, and inflammatory conditions. Founded in 1999 and incorporated in its modern corporate structure in 2015, the company operates as a research-driven enterprise supported by its major shareholder and strategic partner, Linnane Pharma AB. Hamlet BioPharma develops proprietary therapeutic agents derived from the discovery of HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells), a tumoricidal protein-lipid molecular complex, alongside immune-modulating technologies designed to treat severe medical conditions with high selectivity and minimal toxicity. The company's core product and pipeline portfolio comprises several clinical and preclinical assets across three primary segments: Oncology Therapeutics, Anti-Infective Therapies, and Anti-Inflammatory Immunotherapies. In oncology, the company's lead drug candidate is Alpha1H, a synthetic peptide complex derived from alpha-lactalbumin designed to selectively induce apoptosis in malignant cells while stimulating local immune responses; Alpha1H is in late-stage clinical development for non-muscle invasive bladder cancer (NMIBC), alongside preclinical programs exploring applications in colon cancer, brain tumors, and other solid malignancies. In anti-infectives and inflammatory indications, the company develops recombinant interleukin-1 receptor antagonist (anakinra) formulations as immunotherapeutic alternatives to conventional antibiotics; these programs target recurrent acute cystitis, chronic urinary tract infections, and bladder pain syndrome (BPS) by reducing mucosal inflammation without inducing antimicrobial resistance. Additional pipeline programs include peptide-based therapies targeting Mycobacterium tuberculosis and antibiotic-resistant bacterial pathogens. In recent major company developments, the organization completed a transformative merger between Hamlet Pharma AB and SelectImmune Pharma AB, formally rebranding the combined entity as Hamlet BioPharma AB to integrate oncology and anti-infective immunotherapies into a unified development platform. In conjunction with the restructuring, the company expanded its intellectual property and project portfolio through the acquisition of advanced tuberculosis and anti-inflammatory assets from Linnane Projects AB under an extended collaboration agreement with Linnane Pharma AB. Hamlet BioPharma has advanced its clinical and regulatory footprint internationally, securing Fast Track designation from the United States Food and Drug Administration (FDA) for Alpha1H in bladder cancer following positive Phase II clinical trial endpoints that demonstrated substantial tumor reduction, clearance of malignant cells, and favourable safety profiles. Furthermore, the company reported positive Phase II clinical data for its anakinra immunomodulatory programs in cystitis and pain management, preparing the assets for Phase III pivotal studies and commercial partnership discussions across European and North American pharmaceutical markets.